|
|
 |
|
 |
 |
| |
Pharmacokinetics of a F(ab´)2 scorpion antivenom
in healthy human volunteers |
| |
| Scorpion envenoming in Mexico is a serious health problem (Dehesa-Davila and Possani, 1994) with an incidence of 213,458 cases in 2004 (Anonymous, 2005). The effectiveness of antivenom treatment depends on the potency of the antivenom, its activity spectrum, the time that elapses from the envenomation to the treatment onset, as well as the antivenom pharmacokinetics (PK). |
| |
| The ideal antivenom must adequately reach the different tissues in which venom produces its toxic effect and, once bound to toxin, the complex must be rapidly eliminated (Ismail and Abd-Elsalam, 1998; Boyeretal., 1999; Seifert and Boyer, 2001). Another important aspect is the difference in safety of antivenoms constituted by whole IgG, on one hand, and, on the other hand, F(ab’)2 and F(ab) antivenoms. Adverse events associated with the use of antivenoms are related to their purity and constitution (Theakston et al., 2003). |
| |
| Fabotherapics are used as a specific antidotes in envenomation from scorpion stings, the bites of spiders and different species of snakes. Fabotherapics have a lower mean distribution and elimination times, as well as a larger distribution volume than pure immunoglobulin preparations. With recent F(ab’)2 purification techniques the risks of allergies, anaphylactic shock or serum sickness are reduced. |
| |
|
 |
| |
© Instituto Bioclon S.A. de C.V. 2006 |
Calzada de Tlalpan # 4687, Col. Toriello Guerra. C.P. 14050, México D.F., Tel 56-65-41-11 |
 |
|
